

AMERICAN ASSOCIATION OF  
NEUROLOGICAL SURGEONS

KATHLEEN T. CRAIG, *Executive Director*  
5550 Meadowbrook Drive  
Rolling Meadows, IL 60008  
Phone: 888-566-AANS  
Fax: 847-378-0600  
info@aans.org



American  
Association of  
Neurological  
Surgeons



Congress of  
Neurological  
Surgeons

CONGRESS OF  
NEUROLOGICAL SURGEONS

REGINA SHUPAK, *CEO*  
10 North Martingale Road, Suite 190  
Schaumburg, IL 60173  
Phone: 877-517-1CNS  
FAX: 847-240-0804  
info@1CNS.org

*President*  
SHELLY D. TIMMONS, MD, PHD  
Hershey, Pennsylvania

*President*  
ASHWINI D. SHARAN, MD  
Philadelphia, Pennsylvania

June 29, 2018

Tamara Syrek Jensen, Esq.  
Director, Coverage and Analysis Group  
Office of Clinical Standards and Quality  
Centers for Medicare and Medicaid Services  
7500 Security Blvd.  
Baltimore, MD 21244

**Subject: CMS National Coverage Analysis (NCA) for Vagus Nerve Stimulation (VNS) for Treatment-Resistant Depression (TRD) (CAG-00313R2)**

Dear Ms. Jensen:

The American Association of Neurological Surgeons (AANS), Congress of Neurological Surgeons (CNS), and the American Society for Stereotactic and Functional Neurosurgery (ASSFN), appreciate the opportunity to comment on the above referenced draft coverage decision memo regarding Medicare coverage for vagus nerve stimulation (VNS) for treatment-resistant depression (TRD).

Despite decades of research, patients with TRD continue to have very limited options. In fact, in four decades, there has not been a single new and unique class of medication to address this significantly at-risk population that has reached the market. The only new available therapy that has received Medicare coverage is repetitive transcranial magnetic stimulation (rTMS), the results of which are described below. While VNS for TRD had been FDA approved since 2005, CMS' 2007 National Coverage Determination (NCD) has left Medicare patients without this significant treatment option for their TRD — despite the continuing body of evidence of its efficacy and cost-benefit for society.

Following FDA approval in 2005, the body of evidence for VNS's effectiveness for TRD has continued to grow. Two significant post-market studies have clearly demonstrated the substantial benefit of VNS for patients with TRD.<sup>1,2</sup> In essence, these studies demonstrate the overwhelming advantage of VNS compared to the standard combination of cognitive and pharmacotherapies. In particular, the second study, published in 2017, showed a significantly higher 5-year cumulative response rate (67.6% compared with 40.9%) and a significantly higher remission rate (cumulative first-time remitters, 43.3% compared with 25.7%). These studies represent the largest and longest cohort of patients ever published with TRD and represent a major addition to the medical literature. The outcomes of VNS for TRD far exceed those reported in rTMS trials for TRD, in which response rates are 15-27%, and remission rates are 14-30%.<sup>3</sup> These short-term rTMS outcomes (not accounting for post-rTMS relapse) are significantly inferior to the long-term outcomes reported for VNS, highlighting the important role that VNS therapy can play in the management of TRD.

While cost-analysis is not a part of the metric CMS uses to make coverage decisions, it is useful to bring to your attention the following data. An analysis of the Medicare population with TRD have shown that VNS can reduce annual costs of treatment by 36 percent.<sup>4</sup> Given the growing efficacy data and the cost/

benefit to our payment systems, there are very few data-driven arguments against offering VNS as an option for TRD. Moreover, there is accumulating evidence of the long-term safety of VNS.<sup>5</sup>

The AANS, CNS, and ASSFN concur with comments submitted by the American Psychiatric Association (APA) on September 6, 2006, which support Medicare coverage of VNS for TRD in patients who are deemed appropriate candidates for this device. As neurosurgeons, we look forward to the ongoing collaboration with our colleagues in psychiatry in bringing this method of treatment to these patients.

In 2005, the FDA assessed that this device met the legal standard of reasonable assurance of safety and effectiveness and recommended further studies. The continually growing body of evidence over the last decade suggests that this standard has now been surpassed. TRD is a potentially fatal illness, as suicide continues to be among the top ten causes of death in the United States.<sup>6</sup> Medicare patients who meet the established criteria for this treatment should, therefore, have unfettered access to this life-changing and life-saving therapy.

Thank you for considering our recommendations. Please contact us if you have any questions or need additional information.

Sincerely,



Shelly D. Timmons, MD, PhD, President  
American Association of Neurological Surgeons



Ashwini D. Sharan, MD, President  
Congress of Neurological Surgeons



Robert E. Gross, MD, PhD, President  
American Society for Stereotactic and Functional Neurosurgery

**Staff Contact:**

Catherine Jeakle Hill  
Senior Manager, Regulatory Affairs  
AANS/CNS Washington Office  
25 Massachusetts Avenue, NW, Suite 610  
Washington, DC 20001  
Phone: 202-446-2026  
Fax: 202-628-5264  
E-mail: [chill@neurosurgery.org](mailto:chill@neurosurgery.org)

## **References**

1. Aaronson ST, Carpenter LL, Conway CR, et al.: Vagus nerve stimulation therapy randomized to different amounts of electrical charge for treatment-resistant depression: acute and chronic effects. *Brain Stimulation* 2013;6:631–640
2. Aaronson ST, Sears, P., Ruvuna, F., Bunker, M., Conway, C. R., Dougherty, D. D., et al. (2017). A 5-Year Observational Study of Patients With Treatment-Resistant Depression Treated With Vagus Nerve Stimulation or Treatment as Usual: Comparison of Response, Remission, and Suicidality. *American Journal of Psychiatry*, 174(7), 640–648
3. McClintock SM, Reti IM, Carpenter LL, et al.: Consensus Recommendations for the Clinical Application of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Depression. *Journal of Clinical Psychiatry* 2018;79: pii: 16cs10905.
4. Meyer J, Noronha AM, Brozak S. How Mental Health is Shortchanged by Lack of Reimbursement for Vagus Nerve Stimulation. *Brain Stimulation* 2016; 9:163-5
5. Giordano F., Zicca A, Barba C., et al.: Vagus nerve stimulation: Surgical technique of implantation and revision and related morbidity. *Epilepsia* 2017; 58 Suppl 1:85-90.
6. Health, United States, 2016—With Chartbook on Long-term Trends in Health., USDHHS, CDC